LARA
A Multicentre Phase II trial of Lenvatinib plus PembrolizumAb in Recurrent gynaecological clear cell Adenocarcinomas
GCGS
MOCCA
A Multicentre Phase II Randomised Trial of Durvalumab (MEDI4736) Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas
Trial Number
NCT03405454 (ClinicalTrials.gov Identifier)Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number
VIP
Phase II Study of Intravenous Vinorelbine in Patients With Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer